Sanford C. Bernstein set a $275.00 price objective on UnitedHealth Group (NYSE:UNH) in a report released on Wednesday morning. The brokerage currently has a buy rating on the healthcare conglomerate’s stock.
UNH has been the subject of several other reports. Zacks Investment Research cut UnitedHealth Group from a buy rating to a hold rating in a research note on Wednesday, March 28th. Credit Suisse Group reissued a buy rating on shares of UnitedHealth Group in a research note on Friday, March 9th. JPMorgan Chase boosted their target price on UnitedHealth Group to $266.00 and gave the stock an overweight rating in a research note on Wednesday. Oppenheimer boosted their target price on UnitedHealth Group from $260.00 to $240.00 and gave the stock an outperform rating in a research note on Wednesday, January 17th. Finally, Citigroup boosted their target price on UnitedHealth Group from $235.00 to $268.00 and gave the stock a buy rating in a research note on Wednesday, January 17th. Three equities research analysts have rated the stock with a hold rating and twenty-six have given a buy rating to the company’s stock. UnitedHealth Group currently has a consensus rating of Buy and an average price target of $251.13.
Shares of NYSE UNH opened at $235.06 on Wednesday. UnitedHealth Group has a twelve month low of $166.65 and a twelve month high of $250.79. The company has a quick ratio of 0.73, a current ratio of 0.71 and a debt-to-equity ratio of 0.56. The firm has a market capitalization of $228,136.20, a PE ratio of 23.34, a PEG ratio of 1.36 and a beta of 0.77.
UnitedHealth Group (NYSE:UNH) last issued its quarterly earnings data on Tuesday, April 17th. The healthcare conglomerate reported $3.04 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.91 by $0.13. UnitedHealth Group had a return on equity of 22.06% and a net margin of 5.41%. The business had revenue of $55.19 billion during the quarter, compared to analysts’ expectations of $54.90 billion. During the same period in the previous year, the firm posted $2.37 earnings per share. The company’s revenue was up 13.3% on a year-over-year basis. research analysts anticipate that UnitedHealth Group will post 12.61 EPS for the current year.
In other news, Director Richard T. Burke sold 10,000 shares of the business’s stock in a transaction dated Monday, March 19th. The stock was sold at an average price of $224.36, for a total value of $2,243,600.00. Following the completion of the sale, the director now directly owns 1,771,257 shares of the company’s stock, valued at approximately $397,399,220.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Kenneth Irwin Shine sold 202 shares of the business’s stock in a transaction dated Thursday, April 19th. The shares were sold at an average price of $237.42, for a total value of $47,958.84. Following the completion of the sale, the director now directly owns 28,948 shares of the company’s stock, valued at $6,872,834.16. The disclosure for this sale can be found here. Insiders have sold a total of 77,019 shares of company stock valued at $17,879,133 over the last ninety days. 0.89% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of the company. Chemical Bank lifted its holdings in shares of UnitedHealth Group by 9.1% in the 4th quarter. Chemical Bank now owns 12,384 shares of the healthcare conglomerate’s stock valued at $2,730,000 after purchasing an additional 1,037 shares during the last quarter. Cambridge Investment Research Advisors Inc. raised its stake in UnitedHealth Group by 12.8% during the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 61,872 shares of the healthcare conglomerate’s stock valued at $13,640,000 after acquiring an additional 7,022 shares during the last quarter. Certified Advisory Corp purchased a new stake in UnitedHealth Group during the 4th quarter valued at approximately $505,000. D.B. Root & Company LLC purchased a new stake in UnitedHealth Group during the 4th quarter valued at approximately $358,000. Finally, Hanson McClain Inc. raised its stake in UnitedHealth Group by 60.7% during the 4th quarter. Hanson McClain Inc. now owns 1,416 shares of the healthcare conglomerate’s stock valued at $312,000 after acquiring an additional 535 shares during the last quarter. 86.78% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “UnitedHealth Group (UNH) Given a $275.00 Price Target by Sanford C. Bernstein Analysts” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/22/unitedhealth-group-unh-given-a-275-00-price-target-by-sanford-c-bernstein-analysts.html.
About UnitedHealth Group
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; and Medicaid plans, Children's Health Insurance Program, and health care programs; and health and dental benefits.
Receive News & Ratings for UnitedHealth Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UnitedHealth Group and related companies with MarketBeat.com's FREE daily email newsletter.